InterVene Secures $15 Million Series B Funding to Advance BlueLeaf, a Novel Catheter-Based System for Deep Venous Reflux

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 25, U.S. local time, medical device company InterVene completed a $15 million Series B financing round. The proceeds from this round will be used to support the company’s development of blood control devices, helping patients with deep venous reflux maintain their health.

It is reported that this round of financing was led by 3x5 Partners, with participation from RiverVest Venture Partners and Correlation Ventures.

InterVene, founded in 2011 and headquartered in California, USA, is dedicated to developing novel medical devices to help physicians optimize therapies for venous diseases.

Chronic Venous Insufficiency (CVI) is a condition characterized by elevated venous pressure in the legs, with symptoms including leg swelling, pain, and leg ulcers. Deep Venous Reflux (DVR) is one of several potential causes of CVI; it leads to valvular incompetence in the leg veins, causing blood to flow backward instead of returning to the heart, thereby significantly compromising overall health.

It is estimated that approximately 6.5 million Americans with deep venous reflux (DVR) also suffer from severe chronic venous insufficiency (CVI). Currently, the primary treatments for DVR include compression therapy, leg support, and local wound care; however, these approaches do not fundamentally address deep venous valve incompetence, and compression therapy is not suitable for all patients. In light of this, patients with DVR often face disease progression, such as skin breakdown and chronic ulcers, due to the lack of better therapeutic options.

InterVene has optimized treatment protocols for severe leg vein disease. BlueLeaf, the company’s flagship product, represents the first catheter-based, non-implantable approach that enables physicians to create new venous valves for patients who are unable to effectively pump blood out of their legs and back to the heart.

BlueLeaf is an intravascular device that addresses deep venous reflux without requiring additional implants. The device is designed to establish new venous valves within the patient’s tissue layers, integrating naturally with the venous wall to facilitate blood flow. Equipped with internal valves, BlueLeaf opens and closes as needed based on the patient’s condition to support hemodynamics while preventing complications such as retrograde blood flow into the heart following venous reflux.

3x5 Partners, headquartered in Oregon, USA, is a venture capital firm dedicated to investing in high-growth companies in the healthcare sector and other fields.

RiverVest Venture Partners, founded in 2000 and headquartered in Missouri, USA, is a venture capital firm focused on investing in early-stage life sciences companies to create shareholder value. It has completed 53 investments to date. RiverVest boasts a professional investment team capable of identifying promising companies in the medical device and biopharmaceutical sectors. In addition to providing financial support, RiverVest offers entrepreneurs access to a professional management team to help them scientifically manage their companies and grow their businesses.

Correlation Ventures, founded in 2006 and headquartered in California, USA, is a venture capital firm focused on providing funding to companies in early and late-stage development. It has completed 226 investments to date.

(Compiled by Liu Yujing)